$6.91 Billion in Sales Expected for Eli Lilly and Company (NYSE:LLY) This Quarter

Equities research analysts expect Eli Lilly and Company (NYSE:LLYGet Rating) to report sales of $6.91 billion for the current quarter, according to Zacks. Two analysts have provided estimates for Eli Lilly and’s earnings, with the lowest sales estimate coming in at $6.70 billion and the highest estimate coming in at $7.13 billion. Eli Lilly and reported sales of $6.74 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.5%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Eli Lilly and will report full year sales of $29.01 billion for the current year, with estimates ranging from $28.90 billion to $29.17 billion. For the next fiscal year, analysts forecast that the business will post sales of $30.68 billion, with estimates ranging from $30.23 billion to $31.41 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Eli Lilly and.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.62 EPS for the quarter, beating the consensus estimate of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The company had revenue of $7.81 billion for the quarter, compared to analyst estimates of $7.29 billion. During the same period last year, the company posted $1.87 earnings per share. The firm’s revenue was up 14.8% compared to the same quarter last year.

Several research analysts have commented on the company. Morgan Stanley raised their price objective on Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. The Goldman Sachs Group raised their target price on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Mizuho raised their target price on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Wells Fargo & Company raised their target price on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Finally, StockNews.com downgraded Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $302.56.

In other news, Director Marschall S. Runge bought 202 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The shares were purchased at an average price of $246.78 per share, with a total value of $49,849.56. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $283.80, for a total transaction of $62,436,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,088,551 shares of company stock worth $307,943,730. Corporate insiders own 0.12% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Norges Bank purchased a new position in Eli Lilly and during the 4th quarter worth approximately $2,213,765,000. Capital World Investors grew its position in Eli Lilly and by 13.9% during the 4th quarter. Capital World Investors now owns 19,115,896 shares of the company’s stock worth $5,280,206,000 after purchasing an additional 2,325,514 shares in the last quarter. Two Sigma Advisers LP grew its position in Eli Lilly and by 6,719.9% during the 3rd quarter. Two Sigma Advisers LP now owns 2,025,500 shares of the company’s stock worth $467,992,000 after purchasing an additional 1,995,800 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Eli Lilly and by 38.5% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,525,748 shares of the company’s stock worth $1,254,743,000 after purchasing an additional 1,257,817 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Eli Lilly and by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. Hedge funds and other institutional investors own 82.75% of the company’s stock.

NYSE:LLY traded up $0.81 during mid-day trading on Monday, hitting $291.63. The company had a trading volume of 2,337,673 shares, compared to its average volume of 2,662,391. The business has a fifty day simple moving average of $289.22 and a 200-day simple moving average of $266.49. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.60. Eli Lilly and has a 1 year low of $193.11 and a 1 year high of $314.00. The firm has a market capitalization of $277.10 billion, a price-to-earnings ratio of 43.20, a PEG ratio of 2.27 and a beta of 0.40.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Monday, May 16th will be issued a dividend of $0.98 per share. The ex-dividend date is Friday, May 13th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.34%. Eli Lilly and’s dividend payout ratio (DPR) is presently 58.07%.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.